Karyopharm Therapeutics
KPTI
139 hedge funds and large institutions have $499M invested in Karyopharm Therapeutics in 2022 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 42 increasing their positions, 46 reducing their positions, and 28 closing their positions.
193% more call options, than puts
Call options by funds: $12M | Put options by funds: $4.09M
44% more capital invested
Capital invested by funds: $347M → $499M (+$152M)
0.97% more ownership
Funds ownership: 4.78% → 5.75% (+0.97%)
7% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 28
9% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 46
3% less funds holding
Funds holding: 143 → 139 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$45.3M |
| 2 |
CC
Commodore Capital
New York
|
+$29.6M |
| 3 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
+$16.6M |
| 4 |
Morgan Stanley
New York
|
+$14.5M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$7.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
-$12.6M |
| 2 |
BlackRock
New York
|
-$8.23M |
| 3 |
LOAMS
Lombard Odier Asset Management (Switzerland)
Petit-Lancy,
Switzerland
|
-$7.33M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$3.37M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$3.34M |
KPTI Hedge Fund Activity: Q1 2022 in Review
139 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2022, worth a combined $499M — up 44% from $347M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of KPTI and 26 opened new positions — a net loss of 2 holders — while 46 trimmed existing stakes and 42 added.
The largest buyer was State Street, adding an estimated $45.3M. The largest seller was Alkeon Capital Management, exiting entirely with an estimated $12.6M sold.
- 139 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2022, down from 143 in Q4 2021.
- Funds reported $499M of Karyopharm Therapeutics stock for Q1 2022, up 44% quarter-over-quarter.
- 26 funds opened new Karyopharm Therapeutics positions in Q1 2022 and 28 closed out, a net change of -2 holders.
- The largest Karyopharm Therapeutics buyer in Q1 2022 was State Street, an estimated $45.3M added.
- The largest Karyopharm Therapeutics seller in Q1 2022 was Alkeon Capital Management, an estimated $12.6M sold.
Based on aggregated 13F filings for Q1 2022.